Navigation Links
Powerful drug's surprising, simple method could lead to better treatments
Date:1/16/2012

CHAMPAIGN, Ill. -- With one simple experiment, University of Illinois chemists have debunked a widely held misconception about an often-prescribed drug.

Led by chemistry professor and Howard Hughes Medical Institute early career scientist Martin Burke, the researchers demonstrated that the top drug for treating systemic fungal infections works by simply binding to a lipid molecule essential to yeast's physiology, a finding that could change the direction of drug development endeavors and could lead to better treatment not only for microbial infections but also for diseases caused by ion channel deficiencies.

"Dr. Burke's elegant approach to synthesizing amphotericin B, which has been used extensively as an antifungal for more than 50 years, has now allowed him to expose its elusive mode of action," said Miles Fabian, who oversees medicinal chemistry research grants at the National Institute of General Medical Sciences. The institute is part of the National Institutes of Health, which supported the work. "This work opens up avenues for improving upon current antifungals and developing novel approaches for the discovery of new agents."

Systemic fungal infections are a problem worldwide and affect patients whose immune systems have been compromised, such as the elderly, patients treated with chemotherapy or dialysis, and those with HIV or other immune disorders. A drug called amphotericin (pronounced AM-foe-TARE-uh-sin) has been medicine's best defense against fungal infections since its discovery in the 1950s. It effectively kills a broad spectrum of pathogenic fungi and yeast, and has eluded the resistance that has dogged other antibiotics despite its long history of use.

The downside? Amphotericin is highly toxic.

"When I was in my medical rotations, we called it 'ampho-terrible,' because it's an awful medicine for patients," said Burke, who has an M.D. in addition to a Ph.D. "But its capacity to form ion channels
'/>"/>

Contact: Liz Ahlberg
eahlberg@illinois.edu
217-244-1073
University of Illinois at Urbana-Champaign
Source:Eurekalert  

Page: 1 2 3

Related biology news :

1. Powerful mathematical model greatly improves predictions for species facing climate change
2. 2 top biological imaging centers offer powerful free online tool to researchers and public
3. Zeroing in on more powerful enzymes for degrading persistent pollutants
4. Powerful antibody-based strategy suggests a new therapeutic approach to diabetes and obesity
5. Powerful antioxidant resveratrol prevents metabolic syndrome in lab tests: U of A study
6. New fossils demonstrate that powerful eyes evolved in a twinkling
7. Finding is a feather in the cap for researchers studying birds big, powerful eyes
8. Giant fire-bellied toads brain brims with powerful germ-fighters
9. New device promises safer way to deliver powerful drugs
10. Structure of DNA repair complex reveals workings of powerful cell motor
11. K-State research channels powerful Kansas wind to keep electricity running
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Powerful drug's surprising, simple method could lead to better treatments
(Date:4/9/2015)... April 9, 2015 Synaptics Inc. (NASDAQ: SYNA ... today that it will report financial results for the ... 2015, after the close of market. The company will ... at 2:00 p.m. PT (5:00 p.m. ET), during which ... participate on the live call, analysts and investors should ...
(Date:4/2/2015)... April 2, 2015 At its 2015 ACMG ... City , the American College of Medical Genetics ... directors to its Board.  Members of the ACMG Board ... for forming and advancing its policies and programs. ACMG ... "It,s an eventful time in medical genetics ...
(Date:4/1/2015)...   Medisafe ™, the leading global medication management ... and Android smartphones and tablets, announces ... platform to allow patients to track and correlate their ... patients will be able to visualize in real-time how ... such as glucose levels and blood pressure. ...
Breaking Biology News(10 mins):Synaptics to Report Third Quarter Results on April 23 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2
... release is available in German . ... infants was investigated using the prominent ,Stanford Marshmallow Experiment,: the children ... eat it now or wait and receive a second one if ... several minutes. Interestingly, children that were able to wait for the ...
... March 13, 2013, Shenzhen, China - In a collaborative study ... Institute of Genetics and Developmental Biology, Chinese Academy of Sciences, ... of wild rice Oryza brachyantha . This work provides ... of Oryza genomes. The genus Oryza ...
... up and walked on two legs is considered to be one ... gone to the far ends of the earth and the ... we walk the way we walk. In the latest such ... Africa) have taken a closer look at bipedal kangaroos and wallabies ...
Cached Biology News:Doing business with a parrot 2Whole genome sequencing of wild rice reveals the mechanisms underlying oryza genome evolution 2It's all in the way we move 2
(Date:4/28/2015)... Showcasing continued leadership in the ... company that provides scientifically advanced, age-defying products, has ... Selling Association (DSA) by the DSA Board of ... period, the DSA confirmed that Nerium’s business practices ... the association: to ensure that direct sales consumers ...
(Date:4/28/2015)... 2015  DanDrit Biotech USA , ... for the treatment of colorectal cancer, is pleased to ... with GISCAD Foundation, a highly recognized Italian group with ... The collaboration relates to VIVA, a Phase III adjuvant ... of disease (NED) Stage IV colorectal cancer (CRC). The ...
(Date:4/28/2015)... 2015  US-Australian drug discovery company, Novogen Limited (ASX: ... a letter from NASDAQ informing it that it had ... Rule). In November 2014, the Company ... to submit a plan to regain compliance with the ... $2,500,000 in stockholders, equity as of June 30, 2014; ...
(Date:4/28/2015)... Calverton, Maryland (PRWEB) April 28, 2015 ... Data Warehouse that bring it to the web ... visualization features and user friendly reporting metrics increase ... save reports for convenient recall and access “on-the-go” ... Warehouse was built using client feedback to assist ...
Breaking Biology Technology:Nerium International Receives Direct Selling Association Membership 2Nerium International Receives Direct Selling Association Membership 3DanDrit Biotech USA, Inc. Announces Final Collaboration Agreement with the GISCAD Foundation 2DanDrit Biotech USA, Inc. Announces Final Collaboration Agreement with the GISCAD Foundation 3DanDrit Biotech USA, Inc. Announces Final Collaboration Agreement with the GISCAD Foundation 4Novogen Regains Full Compliance with NASDAQ Listing Rule 2Novogen Regains Full Compliance with NASDAQ Listing Rule 3
... ,, BEIJING, China , May ... or the "Company") a leading developer,manufacturer, and distributor of Shengmingsu brand ... ("PRC"), today announced its,financial results for the quarter ended ... 2010 Highlights, -- Revenue increased 100.5% to $24.9 ...
... RESEARCH TRIANGLE PARK, N.C. , May 12 The International ... Trials and Statistics Unit, is running the Intergroup Exemestane Study (IES).  IES ... early breast cancer and a median follow-up period of 91 months. ... from multiple centers. , , ...
... schedule , , , ... , , ... announce that the Phase 2 ASSERT clinical trial for its lead drug, RVX-208, a ... of dosing for our Phase 2 ASSERT trial, five months ahead of schedule and ...
Cached Biology Technology:Yongye International Announces First Quarter 2010 Results 2Yongye International Announces First Quarter 2010 Results 3Yongye International Announces First Quarter 2010 Results 4Yongye International Announces First Quarter 2010 Results 5Yongye International Announces First Quarter 2010 Results 6Yongye International Announces First Quarter 2010 Results 7Yongye International Announces First Quarter 2010 Results 8Yongye International Announces First Quarter 2010 Results 9Yongye International Announces First Quarter 2010 Results 10Yongye International Announces First Quarter 2010 Results 11Yongye International Announces First Quarter 2010 Results 12Yongye International Announces First Quarter 2010 Results 13Yongye International Announces First Quarter 2010 Results 14Max Neeman International Signs Agreement for Data Management/EDC of Large Phase IV Trials from Multiple Sites 2Resverlogix Completes Dosing for ASSERT Trial 2Resverlogix Completes Dosing for ASSERT Trial 3Resverlogix Completes Dosing for ASSERT Trial 4Resverlogix Completes Dosing for ASSERT Trial 5